Multi-drug resistant Pseudomonas aeruginosa isolation is an independent risk factor for recurrent hemoptysis after bronchial artery embolization in patients with idiopathic bronchiectasis: a retrospective cohort study.
Humans
Hemoptysis
/ diagnosis
Male
Retrospective Studies
Female
Middle Aged
Bronchiectasis
/ diagnosis
Risk Factors
Bronchial Arteries
Aged
Embolization, Therapeutic
/ methods
Drug Resistance, Multiple, Bacterial
Pseudomonas aeruginosa
/ isolation & purification
Recurrence
Pseudomonas Infections
/ diagnosis
Cohort Studies
Follow-Up Studies
BAE
Bronchiectasis
Isolation
MDR-PA
Recurrent hemoptysis
Journal
Respiratory research
ISSN: 1465-993X
Titre abrégé: Respir Res
Pays: England
ID NLM: 101090633
Informations de publication
Date de publication:
26 Oct 2024
26 Oct 2024
Historique:
received:
01
06
2024
accepted:
20
10
2024
medline:
27
10
2024
pubmed:
27
10
2024
entrez:
27
10
2024
Statut:
epublish
Résumé
Currently, there is a lack of research on multi-drug resistant Pseudomonas aeruginosa (MDR-PA) isolation in bronchiectasis-related hemoptysis. The aim of this study to analyze the risk factors for recurrent hemoptysis following bronchial artery embolization (BAE) and compare the recurrent hemoptysis-free rates between MDR-PA, non-MDR-PA, and non-PA isolation. A retrospective study was performed of patients diagnosed with idiopathic bronchiectasis-related recurrent hemoptysis who underwent BAE at an university-affiliated hospital. Patients were categorized based on PA susceptibility tests into non-PA, non-MDR-PA, and MDR-PA groups. Univariate and multivariate Cox regression were conducted to identify independent risk factors for recurrent hemoptysis. The Kaplan-Meier curves was conducted to compare recurrent hemoptysis-free rates after BAE for non-PA, non-MDR-PA, and MDR-PA. A total of 432 patients were included. 181 (41.90%) patients experienced recurrent hemoptysis during a median follow-up period of 25 months. MDR-PA isolation (adjusted hazard ratio (aHR) 2.120; 95% confidence interval (CI) [1.249, 3.597], p = 0.005) was identified as an independent risk factor for recurrent hemoptysis. Antibiotic treatment (aHR 0.666; 95% CI [0.476, 0.932], p = 0.018) reduced the risk of recurrent hemoptysis. The cumulative recurrent hemoptysis-free rates for non-PA, non-MDR-PA, and MDR-PA were as follows: at 3 months, 88.96%, 88.24%, and 75.86%, respectively; at 1 year, 73.13%, 69.10%, and 51.72%; and at 3 years, 61.91%, 51.69%, and 41.10% (p = 0.034). MDR-PA isolation was an independent risk factor of recurrent hemoptysis post-BAE. Reducing the occurrence of MDR-PA may effectively decrease the recurrence rates of hemoptysis.
Sections du résumé
BACKGROUND
BACKGROUND
Currently, there is a lack of research on multi-drug resistant Pseudomonas aeruginosa (MDR-PA) isolation in bronchiectasis-related hemoptysis. The aim of this study to analyze the risk factors for recurrent hemoptysis following bronchial artery embolization (BAE) and compare the recurrent hemoptysis-free rates between MDR-PA, non-MDR-PA, and non-PA isolation.
METHODS
METHODS
A retrospective study was performed of patients diagnosed with idiopathic bronchiectasis-related recurrent hemoptysis who underwent BAE at an university-affiliated hospital. Patients were categorized based on PA susceptibility tests into non-PA, non-MDR-PA, and MDR-PA groups. Univariate and multivariate Cox regression were conducted to identify independent risk factors for recurrent hemoptysis. The Kaplan-Meier curves was conducted to compare recurrent hemoptysis-free rates after BAE for non-PA, non-MDR-PA, and MDR-PA.
RESULTS
RESULTS
A total of 432 patients were included. 181 (41.90%) patients experienced recurrent hemoptysis during a median follow-up period of 25 months. MDR-PA isolation (adjusted hazard ratio (aHR) 2.120; 95% confidence interval (CI) [1.249, 3.597], p = 0.005) was identified as an independent risk factor for recurrent hemoptysis. Antibiotic treatment (aHR 0.666; 95% CI [0.476, 0.932], p = 0.018) reduced the risk of recurrent hemoptysis. The cumulative recurrent hemoptysis-free rates for non-PA, non-MDR-PA, and MDR-PA were as follows: at 3 months, 88.96%, 88.24%, and 75.86%, respectively; at 1 year, 73.13%, 69.10%, and 51.72%; and at 3 years, 61.91%, 51.69%, and 41.10% (p = 0.034).
CONCLUSION
CONCLUSIONS
MDR-PA isolation was an independent risk factor of recurrent hemoptysis post-BAE. Reducing the occurrence of MDR-PA may effectively decrease the recurrence rates of hemoptysis.
Identifiants
pubmed: 39462395
doi: 10.1186/s12931-024-03019-2
pii: 10.1186/s12931-024-03019-2
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
385Subventions
Organisme : 1.3.5 project for disciplines of excellence-Clinical Research Incubation Project, West China Hospital, Sichuan University
ID : 2019HXFH008
Informations de copyright
© 2024. The Author(s).
Références
McShane PJ, Naureckas ET, Tino G, Strek ME. Non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2013;188(6):647–56.
doi: 10.1164/rccm.201303-0411CI
pubmed: 23898922
Guan WJ, Han XR, de la Rosa-Carrillo D, Martinez-Garcia MA. The significant global economic burden of bronchiectasis: a pending matter. Eur Respir J 2019, 53(2).
Dhar R, Singh S, Talwar D, Mohan M, Tripathi SK, Swarnakar R, Trivedi S, Rajagopala S, D’Souza G, Padmanabhan A, et al. Bronchiectasis in India: results from the European Multicentre Bronchiectasis Audit and Research Collaboration (EMBARC) and Respiratory Research Network of India Registry. Lancet Global Health. 2019;7(9):e1269–79.
doi: 10.1016/S2214-109X(19)30327-4
pubmed: 31402007
Aksamit TR, O’Donnell AE, Barker A, Olivier KN, Winthrop KL, Daniels MLA, Johnson M, Eden E, Griffith D, Knowles M, et al. Adult patients with bronchiectasis: a First look at the US Bronchiectasis Research Registry. Chest. 2017;151(5):982–92.
doi: 10.1016/j.chest.2016.10.055
pubmed: 27889361
Abdulmalak C, Cottenet J, Beltramo G, Georges M, Camus P, Bonniaud P, Quantin C. Haemoptysis in adults: a 5-year study using the French nationwide hospital administrative database. Eur Respir J. 2015;46(2):503–11.
doi: 10.1183/09031936.00218214
pubmed: 26022949
Davidson K, Shojaee S. Managing massive Hemoptysis. Chest. 2020;157(1):77–88.
doi: 10.1016/j.chest.2019.07.012
pubmed: 31374211
Mondoni M, Carlucci P, Job S, Parazzini EM, Cipolla G, Pagani M, Tursi F, Negri L, Fois A, Canu S et al. Observational, multicentre study on the epidemiology of haemoptysis. Eur Respir J 2018, 51(1).
Luo L, Luo J, Jiang Y. A retrospective analysis of risk factors for massive hemoptysis in patients with bronchiectasis. BMC Pulm Med. 2022;22(1):214.
doi: 10.1186/s12890-022-02006-x
pubmed: 35650568
pmcid: 9161452
Kathuria H, Hollingsworth HM, Vilvendhan R, Reardon C. Management of life-threatening hemoptysis. J Intensive care. 2020;8:23.
doi: 10.1186/s40560-020-00441-8
pubmed: 32280479
pmcid: 7132983
Yan HT, Lu GD, Huang XZ, Zhang DZ, Ge KY, Zhang JX, Liu J, Liu S, Zu QQ, Shi HB. A Nomogram to predict recurrence after bronchial artery embolization for Hemoptysis due to Bronchiectasis. Cardiovasc Intervent Radiol. 2021;44(10):1609–17.
doi: 10.1007/s00270-021-02923-0
pubmed: 34282490
Wang LL, Lu HW, Li LL, Gao YH, Xu YH, Li HX, Xi YZ, Jiang FS, Ling XF, Wei W, et al. Pseudomonas aeruginosa isolation is an important predictor for recurrent hemoptysis after bronchial artery embolization in patients with idiopathic bronchiectasis: a multicenter cohort study. Respir Res. 2023;24(1):84.
doi: 10.1186/s12931-023-02391-9
pubmed: 36934266
pmcid: 10024824
Reyes J, Komarow L, Chen L, Ge L, Hanson BM, Cober E, Herc E, Alenazi T, Kaye KS, Garcia-Diaz J, et al. Global epidemiology and clinical outcomes of carbapenem-resistant Pseudomonas aeruginosa and associated carbapenemases (POP): a prospective cohort study. Lancet Microbe. 2023;4(3):e159–70.
doi: 10.1016/S2666-5247(22)00329-9
pubmed: 36774938
pmcid: 10016089
Finch S, McDonnell MJ, Abo-Leyah H, Aliberti S, Chalmers JD. A comprehensive analysis of the impact of Pseudomonas aeruginosa colonization on prognosis in Adult Bronchiectasis. Annals Am Thorac Soc. 2015;12(11):1602–11.
Pieters A, Bakker M, Hoek RAS, Altenburg J, van Westreenen M, Aerts J, van der Eerden MM. Predicting factors for chronic colonization of Pseudomonas aeruginosa in bronchiectasis. Eur J Clin Microbiol Infect Diseases: Official Publication Eur Soc Clin Microbiol. 2019;38(12):2299–304.
doi: 10.1007/s10096-019-03675-z
Araujo D, Shteinberg M, Aliberti S, Goeminne PC, Hill AT, Fardon TC, Obradovic D, Stone G, Trautmann M, Davis A et al. The independent contribution of Pseudomonas aeruginosa infection to long-term clinical outcomes in bronchiectasis. Eur Respir J 2018, 51(2).
Hill AT, Sullivan AL, Chalmers JD, De Soyza A, Elborn SJ, Floto AR, Grillo L, Gruffydd-Jones K, Harvey A, Haworth CS, et al. British thoracic Society Guideline for bronchiectasis in adults. Thorax. 2019;74(Suppl 1):1–69.
doi: 10.1136/thoraxjnl-2018-212463
pubmed: 30545985
Wolff BJ, Bramley AM, Thurman KA, Whitney CG, Whitaker B, Self WH, Arnold SR, Trabue C, Wunderink RG, McCullers J, et al. Improved detection of respiratory pathogens by Use of High-Quality Sputum with TaqMan array Card Technology. J Clin Microbiol. 2017;55(1):110–21.
doi: 10.1128/JCM.01805-16
pubmed: 27795345
Hirshberg B, Biran I, Glazer M, Kramer MR. Hemoptysis: etiology, evaluation, and outcome in a tertiary referral hospital. Chest. 1997;112(2):440–4.
doi: 10.1378/chest.112.2.440
pubmed: 9266882
Ibrahim WH. Massive haemoptysis: the definition should be revised. Eur Respir J. 2008;32(4):1131–2.
doi: 10.1183/09031936.00080108
pubmed: 18827169
Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–81.
doi: 10.1111/j.1469-0691.2011.03570.x
pubmed: 21793988
Chalmers JD, Smith MP, McHugh BJ, Doherty C, Govan JR, Hill AT. Short- and long-term antibiotic treatment reduces airway and systemic inflammation in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med. 2012;186(7):657–65.
doi: 10.1164/rccm.201203-0487OC
pubmed: 22744718
Chen YF, Hou HH, Chien N, Lu KZ, Lin CH, Liao YC, Lor KL, Chien JY, Chen CM, Chen CY, et al. The clinical impacts of lung microbiome in bronchiectasis with fixed airflow obstruction: a prospective cohort study. Respir Res. 2024;25(1):308.
doi: 10.1186/s12931-024-02931-x
pubmed: 39143556
pmcid: 11325704
Sharma S, Mohler J, Mahajan SD, Schwartz SA, Bruggemann L, Aalinkeel R. Microbial Biofilm: a review on formation, infection, Antibiotic Resistance, Control measures, and innovative treatment. Microorganisms 2023, 11(6).
Xiu W, Dong H, Chen X, Wan L, Lu L, Yang K, Yuwen L, Li Q, Ding M, Zhang Y, et al. Metabolic modulation-mediated antibiotic and Immune activation for treatment of chronic lung infections. ACS Nano. 2024;18(23):15204–17.
doi: 10.1021/acsnano.4c03527
pubmed: 38803167
Zeng T, Liu S, Zou P, Yao X, Chen Q, Wei L, Wang Q, Zhang C, Zheng Y, Yu R. Create artilysins from a recombinant library to serve as bactericidal and antibiofilm agents targeting Pseudomonas aeruginosa. Int J Biol Macromol. 2024;273(Pt 2):132990.
doi: 10.1016/j.ijbiomac.2024.132990
pubmed: 38857719
Antimicrobial Resistance C. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629–55.
doi: 10.1016/S0140-6736(21)02724-0
Chang CH, Chang CH, Huang SH, Lee CS, Ko PC, Lin CY, Hsieh MH, Huang YT, Lin HC, Li LF, et al. Epidemiology and outcomes of multidrug-resistant bacterial infection in non-cystic fibrosis bronchiectasis. Ann Clin Microbiol Antimicrob. 2024;23(1):15.
doi: 10.1186/s12941-024-00675-6
pubmed: 38350983
pmcid: 10865664
Conceicao M, Shteinberg M, Goeminne P, Altenburg J, Chalmers JD. Eradication treatment for Pseudomonas aeruginosa infection in adults with bronchiectasis: a systematic review and meta-analysis. Eur Respir Rev 2024, 33(171).
Oliveira VC, Macedo AP, Melo LDR, Santos SB, Hermann PRS, Silva-Lovato CH, Paranhos HFO, Andrade D, Watanabe E. Bacteriophage cocktail-mediated inhibition of Pseudomonas aeruginosa Biofilm on Endotracheal Tube Surface. Antibiot (Basel Switzerland) 2021, 10(1).
Amankwah S, Adisu M, Gorems K, Abdella K, Kassa T. Assessment of phage-mediated inhibition and removal of Multidrug-Resistant Pseudomonas aeruginosa Biofilm on Medical implants. Infect drug Resist. 2022;15:2797–811.
doi: 10.2147/IDR.S367460
pubmed: 35668859
pmcid: 9166914
Vidaillac C, Chotirmall SH. Pseudomonas aeruginosa in bronchiectasis: infection, inflammation, and therapies. Expert Rev Respir Med. 2021;15(5):649–62.
doi: 10.1080/17476348.2021.1906225
pubmed: 33736539